Centessa Pharmaceuticals PLC has a consensus price target of $8.63, established from looking at the 21 latest analyst ratings. The last 3 analyst ratings were released from Morgan Stanley, BMO Capital, and Jefferies on June 21, 2024, April 1, 2024, and November 15, 2023. With an average price target of $12.33 between Morgan Stanley, BMO Capital, and Jefferies, there's an implied 40.63% upside for Centessa Pharmaceuticals PLC from these 3 analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
06/21/2024 | Buy Now | 25.43% | Morgan Stanley | Matthew Harrison | $8 → $11 | Maintains | Equal-Weight | Get Alert |
04/01/2024 | Buy Now | 71.04% | BMO Capital | Kostas Biliouris | $15 → $15 | Maintains | Outperform | Get Alert |
11/15/2023 | Buy Now | 25.43% | Jefferies | Kelly Shi | $4 → $11 | Upgrade | Hold → Buy | Get Alert |
10/26/2023 | Buy Now | -8.78% | Morgan Stanley | Matthew Harrison | $4 → $8 | Upgrade | Underweight → Equal-Weight | Get Alert |
08/15/2023 | Buy Now | 25.43% | SVB Securities | David Risinger | $6 → $11 | Maintains | Outperform | Get Alert |
08/15/2023 | Buy Now | 14.03% | Guggenheim | Debjit Chattopadhyay | $9 → $10 | Maintains | Buy | Get Alert |
08/15/2023 | Buy Now | -42.99% | Goldman Sachs | Salveen Richter | $4.5 → $5 | Maintains | Neutral | Get Alert |
07/25/2023 | Buy Now | 71.04% | BMO Capital | Kostas Biliouris | $11 → $15 | Maintains | Outperform | Get Alert |
06/21/2023 | Buy Now | — | Evercore ISI Group | Umer Raffat | — | Initiates | → Outperform | Get Alert |
06/12/2023 | Buy Now | 2.62% | Guggenheim | Debjit Chattopadhyay | → $9 | Initiates | → Buy | Get Alert |
05/15/2023 | Buy Now | -48.69% | Goldman Sachs | Salveen Richter | $4 → $4.5 | Maintains | Neutral | Get Alert |
03/17/2023 | Buy Now | -31.58% | SVB Leerink | David Risinger | → $6 | Initiates | → Outperform | Get Alert |
01/24/2023 | Buy Now | -54.39% | Morgan Stanley | Matthew Harrison | $5 → $4 | Maintains | Underweight | Get Alert |
08/12/2022 | Buy Now | -42.99% | Morgan Stanley | Matthew Harrison | $10 → $5 | Downgrade | Overweight → Underweight | Get Alert |
08/11/2022 | Buy Now | 25.43% | BMO Capital | Kostas Biliouris | $19 → $11 | Maintains | Outperform | Get Alert |
08/11/2022 | Buy Now | -54.39% | Goldman Sachs | Salveen Richter | $5 → $4 | Maintains | Neutral | Get Alert |
07/15/2022 | Buy Now | 14.03% | Morgan Stanley | Matthew Harrison | $15 → $10 | Maintains | Overweight | Get Alert |
06/17/2022 | Buy Now | 116.65% | BMO Capital | Kostas Biliouris | → $19 | Initiates | → Outperform | Get Alert |
05/24/2022 | Buy Now | 71.04% | Morgan Stanley | Matthew Harrison | $19 → $15 | Maintains | Overweight | Get Alert |
05/24/2022 | Buy Now | -8.78% | Goldman Sachs | Salveen Richter | $12 → $8 | Maintains | Neutral | Get Alert |
04/05/2022 | Buy Now | 116.65% | Morgan Stanley | Matthew Harrison | $20 → $19 | Maintains | Overweight | Get Alert |
The latest price target for Centessa Pharmaceuticals (NASDAQ:CNTA) was reported by Morgan Stanley on June 21, 2024. The analyst firm set a price target for $11.00 expecting CNTA to rise to within 12 months (a possible 25.43% upside). 8 analyst firms have reported ratings in the last year.
The latest analyst rating for Centessa Pharmaceuticals (NASDAQ:CNTA) was provided by Morgan Stanley, and Centessa Pharmaceuticals maintained their equal-weight rating.
The last upgrade for Centessa Pharmaceuticals PLC happened on November 15, 2023 when Jefferies raised their price target to $11. Jefferies previously had a hold for Centessa Pharmaceuticals PLC.
The last downgrade for Centessa Pharmaceuticals PLC happened on August 12, 2022 when Morgan Stanley changed their price target from $10 to $5 for Centessa Pharmaceuticals PLC.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Centessa Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Centessa Pharmaceuticals was filed on June 21, 2024 so you should expect the next rating to be made available sometime around June 21, 2025.
While ratings are subjective and will change, the latest Centessa Pharmaceuticals (CNTA) rating was a maintained with a price target of $8.00 to $11.00. The current price Centessa Pharmaceuticals (CNTA) is trading at is $8.77, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.